trial
as of 2026-07-01Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
NCTId NCT00300963
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
275
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-12
Primary completion
2005-10
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Sponsors
GlaxoSmithKlineLead Sponsor
Sites
20 total
Little Rock, United StatesAnaheim, United StatesCerritos, United StatesGarden Grove, United StatesGlendale, United StatesNational City, United StatesOceanside, United StatesPico Rivera, United StatesRosemead, United StatesSan Diego, United StatesUpland, United StatesWashington D.C., United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
275
Phase
PHASE2
Primary Completion Date
2005-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication